Comparative Pharmacology
Head-to-head clinical analysis: DURAQUIN versus PRONESTYL SR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DURAQUIN versus PRONESTYL SR.
DURAQUIN vs PRONESTYL-SR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Quinidine is a class Ia antiarrhythmic agent that blocks sodium channels, slowing phase 0 depolarization, prolongs the action potential duration, and increases the effective refractory period. It also exhibits anticholinergic and negative inotropic effects.
Class Ia antiarrhythmic agent; blocks sodium channels, slowing phase 0 depolarization and decreasing myocardial excitability; also prolongs refractory period and has anticholinergic effects.
Quinidine sulfate 324 mg orally every 8-12 hours, adjusted based on serum quinidine levels.
500–1000 mg orally every 6 hours (sustained-release). Maximum 1.5 g per dose or 4 g per day.
None Documented
None Documented
Terminal elimination half-life is 8-12 hours in adults with normal renal and hepatic function. Clinically, dose adjustment may be needed in renal impairment (half-life prolonged to up 18 hours) or hepatic impairment.
2.5-4.7 hours (procainamide); 6-9 hours (NAPA, active metabolite). Prolonged in renal impairment (up to 11-20 hours for procainamide, 30-42 hours for NAPA).
Primarily hepatic metabolism (90-95%) to inactive metabolites, with renal excretion of unchanged drug <5% and metabolites. Fecal elimination accounts for <5% due to biliary excretion of metabolites.
Renal excretion: ~50-60% unchanged drug (procainamide), ~15-30% as N-acetylprocainamide (NAPA). Biliary/fecal: minor (<5%).
Category C
Category C
Antiarrhythmic
Antiarrhythmic